drugset / Trial / NCT03841292

Using Non-invasive Brain Stimulation (tDCS) With Varenicline for Treating Tobacco Dependence

NCT03841292

RandomizedParallel-groupDouble-blindTreatment

Summary

The addition of tDCS as an adjunct to pharmacotherapy is a novel approach but one that is grounded in a growing evidence-base.The primary objective of this research is to provide preliminary evidence of the effectiveness of tDCS as an adjunct treatment to pharmacotherapy for smoking cessation. The investigators hypothesize that the addition of active tDCS to the left DLPFC will improve the effectiveness of varenicline as reflected by higher quit rates at end of treatment compared to the sham group. Smoking status will be biochemically confirmed at various time points using expired cotinine measures. Furthermore, the investigators will be collecting neuroimaging (fMRI) data as well as measures of attentional bias to explore the neurological and physiological correlates from using adjunct tDCS and varenicline therapy.

Timeline

Start
2018-10-01
Primary completion
2022-01-31
Completion
2022-01-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Varenicline Small molecule 1 mg Oral

Indications